Cargando…

Oral histone deacetylase inhibitor tucidinostat (HBI‐8000) in patients with relapsed or refractory adult T‐cell leukemia/lymphoma: Phase IIb results

This multicenter, prospective phase IIb trial evaluating the efficacy and safety of tucidinostat (HBI‐8000) in patients with relapsed or refractory (R/R) adult T‐cell leukemia/lymphoma (ATLL) was undertaken in Japan. Eligible patients had R/R ATLL and had failed standard of care treatment with chemo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Utsunomiya, Atae, Izutsu, Koji, Jo, Tatsuro, Yoshida, Shinichiro, Tsukasaki, Kunihiro, Ando, Kiyoshi, Choi, Ilseung, Imaizumi, Yoshitaka, Kato, Koji, Kurosawa, Mitsutoshi, Kusumoto, Shigeru, Miyagi, Takashi, Ohtsuka, Eiichi, Sasaki, Osamu, Shibayama, Hirohiko, Shimoda, Kazuya, Takamatsu, Yasushi, Takano, Kuniko, Yonekura, Kentaro, Makita, Shinichi, Taguchi, Jun, Gillings, Mireille, Onogi, Hiroshi, Tobinai, Kensei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357668/ https://www.ncbi.nlm.nih.gov/pubmed/35579212 http://dx.doi.org/10.1111/cas.15431

Ejemplares similares

Oral histone deacetylase inhibitor HBI-8000 (tucidinostat) in Japanese patients with relapsed or refractory non-Hodgkin’s lymphoma: phase I safety and efficacy
por: Yoshimitsu, Makoto, et al.
Publicado: (2022)

Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results
por: Rai, Shinya, et al.
Publicado: (2022)

The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors
por: Bissonnette, Reid P., et al.
Publicado: (2021)

Induction of apoptosis by HBI‐8000 in adult T‐cell leukemia/lymphoma is associated with activation of Bim and NLRP3
por: Hasegawa, Hiroo, et al.
Publicado: (2016)

HBI-8000, HUYABIO Lead Clinical Program, Is a Selective Histone Deacetylase Inhibitor With Therapeutic Benefits in Leukemia and in Solid Tumors
por: Shojaei, Farbod, et al.
Publicado: (2022)

An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma
por: Izutsu, Koji, et al.
Publicado: (2023)

Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges
por: Makita, Shinichi, et al.
Publicado: (2019)

Forodesine in the treatment of relapsed/refractory peripheral T-cell lymphoma: an evidence-based review
por: Makita, Shinichi, et al.
Publicado: (2018)

Promising results of an anti-CCR4 antibody, KW-0761, for relapsed Adult T-Cell Leukemia-Lymphoma (ATL)
por: Utsunomiya, Atae, et al.
Publicado: (2011)

Clinical Trials and Treatment of ATL
por: Tsukasaki, Kunihiro, et al.
Publicado: (2012)

Development of a modified prognostic index for patients with aggressive adult T-cell leukemia-lymphoma aged 70 years or younger: possible risk-adapted management strategies including allogeneic transplantation
por: Fuji, Shigeo, et al.
Publicado: (2017)

Altitude 8000
por: Murail, Tristan
Publicado: (1975)

Mogamulizumab for relapsed adult T‐cell leukemia–lymphoma: Updated follow‐up analysis of phase I and II studies
por: Ishida, Takashi, et al.
Publicado: (2017)

Prognosis of patients with adult T‐cell leukemia/lymphoma in Japan: A nationwide hospital‐based study
por: Imaizumi, Yoshitaka, et al.
Publicado: (2020)

Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study
por: Izutsu, Koji, et al.
Publicado: (2021)

LISTENING AND LEARNING TO FORM THE HBI ROAD MAP FOR INDIAN COUNTRY
por: French, Molly, et al.
Publicado: (2019)

Recent advances in the treatment of adult T-cell leukemia-lymphomas
por: Utsunomiya, Atae, et al.
Publicado: (2015)

Epidemiological and clinical features of adult T‐cell leukemia–lymphoma in Japan, 2010–2011: A nationwide survey
por: Nosaka, Kisato, et al.
Publicado: (2017)

Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment
por: Sun, Yichen, et al.
Publicado: (2022)

The Healthy Brain Initiative (HBI): A prospective cohort study protocol
por: Besser, Lilah M., et al.
Publicado: (2023)

A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemia
por: Izutsu, Koji, et al.
Publicado: (2020)

Clinical development of anti‐CD19 chimeric antigen receptor T‐cell therapy for B‐cell non‐Hodgkin lymphoma
por: Makita, Shinichi, et al.
Publicado: (2017)

Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma
por: Makita, Shinichi, et al.
Publicado: (2020)

Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B‐cell lymphoma
por: Munakata, Wataru, et al.
Publicado: (2021)

Can allo-SCT with RIC cure ATLL? Long-term survivors with excellent PS and with heterogenous HTLV-1 proviral load level
por: Uike, Naokuni, et al.
Publicado: (2011)

Clinical characteristics of patients with B-cell lymphoma enrolled in clinical trials for aggressive lymphoma in Japan: Japan Clinical Oncology Group - Lymphoma Study Group study – JCOG0108A
por: Kinoshita, Tomohiro, et al.
Publicado: (2021)

A novel HBI-based ratiometric fluorescent probe for rapid detection of trifluoroborate
por: Liang, Gao, et al.
Publicado: (2023)

Clinical significance of the immunoglobulin G heavy‐chain repertoire in peripheral blood mononuclear cells of adult T‐cell leukaemia–lymphoma patients receiving mogamulizumab
por: Nosaka, Kisato, et al.
Publicado: (2021)

Effects of first-line chemotherapy on natural killer cells in adult T-cell leukemia–lymphoma and peripheral T-cell lymphoma
por: Ogura, Michinori, et al.
Publicado: (2016)

The kinetics of HTLV-1 proviral load after allogeneic hematopoietic cell transplantation with reduced intensity conditioning regimen; a comparison with that from sibling donors and that from unrelated donors
por: Choi, Ilseung, et al.
Publicado: (2014)

Landscape of immunoglobulin heavy chain γ gene class switch recombination in patients with adult T-cell leukemia–lymphoma
por: Hiramatsu, Hiroaki, et al.
Publicado: (2022)

CRY1 interacts directly with HBI1 to regulate its transcriptional activity and photomorphogenesis in Arabidopsis
por: Wang, Sheng, et al.
Publicado: (2018)

Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma
por: Maruyama, Dai, et al.
Publicado: (2018)

Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma
por: Tanaka, Norio, et al.
Publicado: (2022)

Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma
por: Kato, Koji, et al.
Publicado: (2021)

Safety, tolerability and pharmacokinetics of shorter duration of infusion of obinutuzumab in Japanese patients with B-cell non-Hodgkin lymphoma: final results of the phase II GATS study
por: Ohmachi, Ken, et al.
Publicado: (2018)

Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T‐cell lymphoma
por: Maruyama, Dai, et al.
Publicado: (2017)

The blood DNA virome in 8,000 humans
por: Moustafa, Ahmed, et al.
Publicado: (2017)

Epidemiology of adult T‐cell leukemia‐lymphoma in Japan: An updated analysis, 2012‐2013
por: Ito, Shigeki, et al.
Publicado: (2021)

A phase I/II study of 10-min dosing of bendamustine hydrochloride (rapid infusion formulation) in patients with previously untreated indolent B-cell non-Hodgkin lymphoma, mantle cell lymphoma, or relapsed/refractory diffuse large B-cell lymphoma in Japan
por: Ishizawa, Kenichi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_e3104lfj5epa4na5rlcmq20rlf